Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bellevue Group AG

Bellevue Group AG lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 42.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 473,915 shares of the company’s stock after selling 347,885 shares during the quarter. Bellevue Group AG owned about 0.39% of Apellis Pharmaceuticals worth $27,857,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in APLS. Future Financial Wealth Managment LLC acquired a new stake in Apellis Pharmaceuticals in the first quarter valued at approximately $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Apellis Pharmaceuticals in the first quarter valued at approximately $89,000. CWA Asset Management Group LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $205,000. Woodward Diversified Capital LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $210,000. Finally, HC Advisors LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $210,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Buying and Selling

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the completion of the sale, the director now directly owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 78,907 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total value of $3,341,711.45. Following the completion of the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at $47,261,880.05. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the sale, the director now directly owns 136,998 shares of the company’s stock, valued at approximately $5,375,801.52. The disclosure for this sale can be found here. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

Shares of APLS traded up $0.87 during mid-day trading on Friday, reaching $39.75. 1,185,400 shares of the company’s stock were exchanged, compared to its average volume of 1,481,348. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.77 and a quick ratio of 3.02. The stock has a market capitalization of $4.82 billion, a PE ratio of -11.49 and a beta of 0.88. The business’s fifty day simple moving average is $39.58 and its 200-day simple moving average is $51.70. Apellis Pharmaceuticals, Inc. has a 52-week low of $19.83 and a 52-week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The firm had revenue of $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. During the same period last year, the company earned ($1.56) earnings per share. The company’s revenue for the quarter was up 284.3% on a year-over-year basis. On average, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Robert W. Baird reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, July 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, May 8th. UBS Group dropped their price target on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Wedbush dropped their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Mizuho dropped their price target on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating on the stock in a research note on Monday, April 29th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $74.75.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).